Karin Havenith
Impact in
-
- Lymphoma Diagnosis and Treatment
- Oncology top 10%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Lymphoma Diagnosis and Treatment 15
- Oncology 10
- CAR-T cell therapy research 6
- Cancer Immunotherapy and Biomarkers 2
- Co-authors
- Jay Marshall Feingold (8 shared papers)Mehdi Hamadani (11 shared papers)Paolo Fabrizio Caimi (10 shared papers)John A. Radford (4 shared papers)David Ungar (4 shared papers)Melhem Solh (4 shared papers)Carmelo Carlo‐Stella (9 shared papers)Brad S. Kahl (4 shared papers)
- Journals
- Blood (7 papers)Hematological Oncology (3 papers)Blood Advances (2 papers)The Lancet Oncology (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)
- Partner nations
- United StatesItalyUnited Kingdom
In The Last Decade
Karin Havenith
27 papers receiving 960 citations
Karin Havenith's Hit Papers
Peers
Comparison fields: 5 of 47
- Pathology and Forensic Medicine 472
- Oncology 252
- Radiology, Nuclear Medicine and Imaging 185
- Immunology 64
- Hematology 40
Countries citing papers authored by Karin Havenith
This map shows the geographic impact of Karin Havenith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Havenith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Havenith more than expected).
Fields of papers citing papers by Karin Havenith
This network shows the impact of papers produced by Karin Havenith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Havenith. The network helps show where Karin Havenith may publish in the future.
Co-authors
The 25 scholars most cited alongside Karin Havenith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Hit paper breakdown → | 2021 | 355 |
| 2 | 2020 | 145 | |
| 3 | 2019 | 86 | |
| 4 | 2021 | 72 | |
| 5 | 2020 | 70 | |
| 6 | 1997 | 46 | |
| 7 | 2020 | 46 | |
| 8 | 2020 | 33 | |
| 9 | 2016 | 15 | |
| 10 | 1995 | 12 | |
| 11 | 2016 | 12 | |
| 12 | 2024 | 12 | |
| 13 | 2024 | 11 | |
| 14 | 2015 | 10 | |
| 15 | 2024 | 10 | |
| 16 | 2017 | 8 | |
| 17 | 2017 | 7 | |
| 18 | 2023 | 7 | |
| 19 | 2021 | 6 | |
| 20 | 2022 | 6 |
About Karin Havenith
Karin Havenith is a scholar working on Pathology and Forensic Medicine, Oncology, Immunology, Radiology, Nuclear Medicine and Imaging and Organic Chemistry, having authored 27 papers that have together received 988 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (15 papers), CAR-T cell therapy research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Synthesis and pharmacology of benzodiazepine derivatives (4 papers), Cancer Immunotherapy and Biomarkers (2 papers), T-cell and B-cell Immunology (2 papers), Acute Lymphoblastic Leukemia research (2 papers) and Toxin Mechanisms and Immunotoxins (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (472 citations), Oncology (252 citations), Radiology, Nuclear Medicine and Imaging (185 citations), Immunology (64 citations) and Hematology (40 citations). Karin Havenith has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Jay Marshall Feingold, Mehdi Hamadani, Paolo Fabrizio Caimi, John A. Radford, David Ungar, Melhem Solh, Carmelo Carlo‐Stella, Brad S. Kahl, Kirit M. Ardeshna and Shui Xiang He. Their work appears in journals such as Blood, Hematological Oncology, Blood Advances, The Lancet Oncology and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.